naringenin and Overweight

naringenin has been researched along with Overweight in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Javad Hosseinzadeh-Attar, M; Mahdi Rezayat, S; Mansouri, S; Naeini, F; Namkhah, Z1
Hosseinzadeh-Attar, MJ; Jazayeri-Tehrani, SA; Mansouri, S; Naeini, F; Namkhah, Z; Rezayat, SM; Tutunchi, H; Yaseri, M1
Hosseinzadeh-Attar, MJ; Mansouri, S; Naeini, F; Namkhah, Z; Rezayat, SM; Tutunchi, H; Yaseri, M1

Trials

3 trial(s) available for naringenin and Overweight

ArticleYear
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    International journal of clinical practice, 2021, Volume: 75, Issue:11

    Topics: Dietary Supplements; Double-Blind Method; Flavanones; Humans; Iran; Lipids; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Probability

2021
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Trials, 2021, Nov-13, Volume: 22, Issue:1

    Topics: Dietary Supplements; Double-Blind Method; Flavanones; Humans; Iran; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Randomized Controlled Trials as Topic

2021
Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: a pilot double-blind, placebo-controlled, randomized clinical trial.
    European journal of gastroenterology & hepatology, 2022, 03-01, Volume: 34, Issue:3

    Topics: Cardiovascular Diseases; Dietary Supplements; Double-Blind Method; Flavanones; Heart Disease Risk Factors; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Overweight; Risk Factors

2022